---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-000419"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2024-01-03T23:59:59+00:00"
generated_at: "2026-06-07T04:35:17.420346+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vistagen receives EPO notice of intention to grant AV-101 patent for neuropathic pain

## Summary
- European Patent Office issued Notice of Intention to Grant patent for AV-101 to treat neuropathic pain.
- Patent will not expire until at least 2034; adds to global AV-101 portfolio.
- Preclinical data show AV-101 similar efficacy to gabapentin and pregabalin with better side effect profile.
- Phase 1 data demonstrate AV-101 well-tolerated with no meaningful difference vs placebo.
- Vistagen plans to seek strategic collaborations to advance AV-101 development.

## SEC filing metadata
- accession: 0001437749-24-000419
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2024-01-03T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000143774924000419/0001437749-24-000419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000143774924000419/vtgn20240103_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-000419
- JSON: https://secwatch.observer/filing/0001437749-24-000419.json
- Plain text: https://secwatch.observer/filing/0001437749-24-000419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.